Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colistin + meropenem + vancomycin
- Development stage
- Preclinical
- Lead developer
- Sumitomo Pharma
- Modality
- Small Molecules
- Administration
- Intravenous, Inhalation
01
Overview
A combination antimicrobial therapy consisting of colistin, meropenem, and vancomycin used primarily for treating severe multidrug-resistant infections, particularly those caused by Acinetobacter baumannii. This triple combination leverages synergistic effects, with colistin disrupting the bacterial outer membrane, allowing vancomycin to reach its targets in the cell wall, while meropenem provides additional carbapenem coverage.
02
Targets
Beyond the preview
Go deeper on colistin + meropenem + vancomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colistin + meropenem + vancomycin.